GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
G

GlaxoSmithKline PLC ADR GSK · USD

Health Care · US listing · 🇺🇸 United States

Compare

51.54

+2.40%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

$32.67bn

FY2016FY2025

Net income

$5.72bn

FY2016FY2025

Free cash flow

$5.82bn

FY2016FY2025

Shareholders' equity

$16.35bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue$32.67bn$31.38bn$30.33bn$29.32bn$24.70bn$24.35bn$33.75bn$30.82bn$30.19bn$27.89bn
Gross profit$23.65bn$22.33bn$21.76bn$19.77bn$16.53bn$16.43bn$21.89bn$20.58bn$19.84bn$18.60bn
Research and development$7.53bn$6.40bn$6.22bn$5.49bn$5.02bn$4.79bn$4.57bn$3.89bn$4.48bn$3.63bn
Operating income$8.34bn$4.02bn$6.75bn$6.43bn$4.36bn$5.98bn$6.96bn$5.48bn$4.09bn$2.60bn
Net income$5.72bn$2.58bn$4.93bn$14.96bn$4.38bn$5.75bn$4.64bn$3.62bn$1.53bn$912.0m
Diluted earnings per share5.601.242.397.312.152.852.311.820.780.46

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets$61.01bn$59.46bn$75.22bn$60.15bn$107.14bn$109.95bn$105.57bn$58.07bn$56.38bn$59.08bn
Cash and short-term investments$3.40bn$3.71bn$6.61bn$7.88bn$5.87bn$8.71bn$6.34bn$3.96bn$3.91bn$4.99bn
Total liabilities$45.02bn$46.38bn$58.91bn$50.05bn$78.23bn$81.50bn$81.25bn$54.39bn$52.89bn$54.12bn
Debt$17.71bn$16.99bn$18.79bn$20.99bn$25.45bn$28.52bn$32.75bn$26.06bn$17.09bn$18.79bn
Shareholders' equity$16.35bn$13.67bn$17.01bn$10.60bn$20.39bn$19.94bn$15.11bn$3.78bn$3.49bn$4.96bn
Shares outstanding1,022m2,073m2,059m2,046m2,038m2,017m2,009m1,991m1,956m1,966m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations$7.14bn$6.55bn$7.89bn$7.40bn$7.95bn$8.44bn$8.02bn$8.42bn$6.92bn$6.50bn
Capital spending−$1.32bn−$2.98bn−$1.63bn−$2.26bn−$2.93bn−$2.24bn−$2.16bn−$1.80bn−$2.20bn−$2.35bn
Free cash flow$5.82bn$3.57bn$6.26bn$5.14bn$5.02bn$6.20bn$5.86bn$6.63bn$4.72bn$4.14bn
Dividends paid−$2.51bn−$2.44bn−$2.79bn−$3.47bn−$4.00bn−$3.98bn−$3.95bn−$3.93bn−$3.91bn−$4.85bn

Latest quarters

By quarter end

Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024Jun 2024
Revenue$7.63bn$8.62bn$8.55bn$7.99bn$7.52bn$8.12bn$8.01bn$7.88bn
Gross profit$5.75bn$5.96bn$6.29bn$5.82bn$5.58bn$5.56bn$5.62bn$5.76bn
Operating income$2.29bn$1.12bn$2.59bn$2.02bn$2.22bn$696.0m$220.0m$1.65bn
Net income$1.74bn$636.0m$2.01bn$1.44bn$1.62bn$414.0m−$58.0m$1.17bn
Diluted earnings per share0.850.621.971.411.590.20-0.030.57
Cash from operations$1.14bn$2.04bn$3.03bn$2.10bn$1.15bn$2.33bn$2.15bn$1.11bn
Capital spending−$443.0m−$560.0m−$428.0m−$633.0m−$448.0m−$1.14bn−$842.0m−$442.0m
Free cash flow$698.0m$1.48bn$2.60bn$1.46bn$697.0m$1.19bn$1.31bn$671.0m
Total assets$82.91bn$61.01bn$82.58bn$81.20bn$78.35bn$59.46bn$58.05bn$73.40bn
Cash and short-term investments$4.54bn$3.40bn$4.45bn$4.96bn$5.79bn$3.71bn$3.21bn$3.77bn
Debt$6.65bn$17.71bn$18.74bn$18.11bn$19.00bn$16.99bn$16.06bn$4.25bn
Shareholders' equity$23.54bn$16.35bn$21.74bn$20.27bn$18.27bn$13.67bn$14.01bn$18.17bn

Financial ratios

Data as of 9 Sept 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin72.4%71.2%71.8%67.4%66.9%67.4%
Operating margin25.5%12.8%22.2%21.9%17.6%24.6%
Net margin17.5%8.2%16.2%51.0%17.8%23.6%
Return on equity35.0%18.8%29.0%141.1%21.5%28.8%
Return on assets9.4%4.3%6.6%24.9%4.1%5.2%
Free cash flow yield8.5%9.5%9.5%9.7%11.0%10.9%
Revenue growth4.1%3.5%3.4%18.7%1.4%-27.8%
Earnings growth122.0%-47.7%-67.1%241.1%-23.7%23.8%
Current ratio0.82x0.78x0.88x0.91x0.79x0.91x
Debt to equity1.04x1.17x1.04x1.98x1.25x1.43x
Equity ratio26.8%23.0%22.6%17.6%19.0%18.1%
Interest coverage12.14x6.11x8.70x7.52x5.56x6.70x
R&D as a share of sales23.0%20.4%20.5%18.7%20.3%19.7%
Buybacks as a share of market value1.4%-0.7%-0.7%-0.4%-1.0%-0.4%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue3.7%6.0%3.2%
Operating income9.0%6.9%-2.1%
Net income-27.4%-0.1%-3.8%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin71.8%70.7%69.7%67.8%
Operating margin19.3%20.6%20.8%20.5%
Net margin12.9%22.8%22.2%18.0%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings8.827.215.54.820.913.120.721.446.184.5
Price to sales1.52.22.52.53.73.12.92.52.32.8

Market value over time

31 Oct 2016 to 8 Sept 2026, in USD

$79.87bn$98.58bn

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return43%-8%5%-20%19%-23%25%7%-8%-5%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 5-to-4 reverse split · 19 Jul 2022
  • 2-for-1 split · 12 Nov 1991

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.